secwatch.observer — SEC 8-K summary
======================================

Issuer:     MapLight Therapeutics, Inc. (MPLT)
CIK:        0001770069
Form:       8-K
Filed at:   2026-07-27T11:07:27+00:00
Accession:  0001193125-26-316820
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MapLight reports positive Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia
--------------------------------------------------------------------------------

- Primary endpoint met: 210/3 mg BID dose showed statistically significant PANSS total score reduction vs placebo (effect size 0.37, p=0.015, LS mean diff -4.5).
- Cognitive performance improved in patients with baseline impairment (effect size 0.51, p=0.041) on prespecified secondary endpoint.
- ML-007C-MA was well tolerated with no serious or drug-related severe adverse events; all-cause discontinuation low at 19.9%.
- Company plans End-of-Phase 2 FDA meeting and additional confirmatory trial to support NDA submission.
- Also reported positive IRIS Phase 2 results for ML-004 in autism irritability; plans FDA EOP2 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/0001193125-26-316820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/d139086d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-316820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer